Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. develops plant-derived prescription medicines for gastrointestinal disease states in people and animals. Its human-health news centers on crofelemer, including Mytesi for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and rare-disease intestinal failure programs tied to microvillus inclusion disease and short bowel syndrome through Napo Pharmaceuticals and Napo Therapeutics.
Company updates also cover animal-health products such as conditionally approved Canalevia-CA1 for chemotherapy-induced diarrhea in dogs and the Neonorm franchise for gut health in animals. Recurring corporate news includes Nasdaq listing-compliance matters, reverse stock splits, warrant exercises, stockholder meetings, proxy proposals, and other capital-structure actions.
Jaguar Health (NASDAQ:JAGX) reported second-quarter 2026 net revenue of $1.2 million, down 59% year over year, as product revenue fell 60% to $1.18 million following the U.S. commercialization transfer of Mytesi and Canalevia-CA1 to Future Pak affiliate Woodward Specialty.
License and grant revenue were $43,000. Loss from operations narrowed to $7.6 million from $8.0 million, helped by operating expense reductions, including a drop in sales and marketing expense from about $2.5 million to roughly $5,000. Net loss attributable to common stockholders increased to $12.7 million. Non-GAAP recurring EBITDA was a loss of $8.4 million, versus a $7.9 million loss a year earlier.
According to Jaguar Health, it satisfied closing conditions to receive a non-dilutive $2 million holdback from Future Pak and continues advancing crofelemer for rare intestinal failure diseases, targeting completion of the NDA clinical package for microvillus inclusion disease by end of 2026 and an NDA filing in Q2 2027.
Jaguar Health (NASDAQ:JAGX) plans to file its Form 10-Q earnings report for the quarter ended June 30, 2026 on August 19, 2026. The company will host an investor webcast the same day at 4:30 p.m. Eastern to review Q2 2026 financials and provide corporate updates.
A replay of the webcast will be available in the investor relations section of Jaguar Health’s website. Jaguar and its family companies Napo Pharmaceuticals, Napo Therapeutics, and Magdalena Biosciences focus on plant-derived prescription drugs for complicated gastrointestinal and mental health indications.
Jaguar Health (NASDAQ:JAGX) announced that it has satisfied the conditions to receive a non-dilutive $2 million holdback payment from Future Pak related to a January 2026 U.S. commercial licensing agreement for Mytesi and Canalevia-CA1. Jaguar previously received a partial upfront fee of $16 million at closing and an additional $3 million payment in March 2026, and, according to the company, may receive up to $17 million more in milestone and other future payments under the agreement.
Future Pak is the exclusive U.S. marketer for Mytesi, approved for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, and Canalevia-CA1, for chemotherapy-induced diarrhea in dogs. Jaguar highlighted that this deal supports its focus on developing liquid oral crofelemer for rare intestinal failure (IF) conditions such as microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF). At ESPGHAN 2026, Jaguar’s subsidiary Napo reported ongoing investigational data in pediatric IF patients showing reductions in parenteral support normalized to body weight of up to 48% in one MVID patient and up to 40% in two SBS-IF patients after more than 12 months of high-dose liquid oral crofelemer, with no significant clinical or laboratory abnormalities reported.
Jaguar Health (NASDAQ:JAGX) reported positive exploratory market research supporting the commercial opportunity for Neonorm Dog, a plant-based, non-prescription product designed to support normal stool consistency and GI fluid balance in dogs. Neonorm Dog extends Jaguar's existing Neonorm franchise, which currently includes Neonorm Foal and Neonorm Calf.
In a directional survey of 33 veterinary oncologists, nearly 90% viewed the Neonorm Dog concept as clinically relevant, almost 80% said they would likely recommend it for selected canine oncology patients, and 69% would recommend owners keep it at home for early loose stool. In an exploratory survey of 18 dog owners, 83% found the concept very or extremely appealing and 94% would definitely or probably purchase the product. Jaguar is finalizing packaging, labeling, and launch preparations and expects to offer Neonorm Dog via select online and animal health retail channels, including Amazon and Chewy, to broaden its companion animal footprint.
Jaguar Health (NASDAQ:JAGX) announced that family company Napo Pharmaceuticals is providing its novel crofelemer powder for oral solution for compassionate use to treat intestinal failure (IF) due to microvillus inclusion disease (MVID) in an infant in the European Union.
According to Jaguar Health, Napo has already supplied oral crofelemer for select infant and pediatric IF patients with MVID in U.S. expanded access programs and for an investigator-initiated proof-of-concept trial in pediatric IF due to MVID and short bowel syndrome (SBS-IF) in the United Arab Emirates. Data presented at ESPGHAN 2026 from ongoing studies showed reductions in weekly parenteral support (PS) requirements normalized to body weight of up to 48% in one MVID patient and up to 40% in two SBS-IF patients after more than 12 months of high-dose oral crofelemer, with no significant clinical or laboratory abnormalities.
Jaguar Health said enrollment is complete in its blinded pivotal trial of liquid oral crofelemer in pediatric MVID patients and plans to seek Breakthrough Therapy Designation and file an NDA with the FDA for MVID in mid-2027, supported by trial and compassionate-use data.
Jaguar Health (NASDAQ:JAGX) and family company Napo reported new data at ESPGHAN 2026 on oral liquid crofelemer as adjunctive therapy for pediatric intestinal failure (IF) due to MVID and SBS.
According to Jaguar, long-term treatment showed up to 48% and 40% PS reductions and no significant abnormalities, with a planned NDA filing for MVID in mid‑2027.
Jaguar Health (NASDAQ:JAGX) will convert all Series O Convertible Preferred Stock, issued as a recent one-time stock dividend, into Common Stock at a rate of 3.209 shares per preferred share at 12:00 pm ET on June 25, 2026.
Cash will be paid for fractional shares based on a $2.68 price. Jaguar highlights its crofelemer program for rare intestinal failure diseases, including MVID and SBS-IF, recent proof-of-concept data with up to 37% parenteral support reduction, and an NDA filing targeted for the first half of 2027.
Jaguar Health (NASDAQ:JAGX) has completed submission of a New Animal Drug Application to the FDA Center for Veterinary Medicine seeking full approval of crofelemer (Canalevia-CA1) for treating chemotherapy-induced diarrhea (CID) in dogs.
The pivotal effectiveness study showed statistically significant results: after 3 days of twice-daily treatment, dogs had average stool considered normal. In owner surveys, 77% believed Canalevia-CA1 was effective, and about 40% reported complete CID resolution versus 10.5% without CID treatment.
Jaguar Health (NASDAQ:JAGX) announced that its board is exploring a range of strategic alternatives, including mergers, reverse mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions. This review is aligned with the anticipated completion of clinical work to support a targeted NDA filing for its crofelemer-based prescription drug candidate for rare intestinal failure diseases.
In an ongoing investigator-initiated proof-of-concept trial in pediatric patients with intestinal failure due to MVID and SBS-IF, crofelemer has shown up to a 37% reduction in parenteral support. A third-party report estimates the nutritional support market for MVID at about $1.1 billion in 2026, rising to approximately $1.5 billion in 2033.
Jaguar Health (NASDAQ:JAGX) announced positive preclinical results from Magdalena Biosciences, its joint venture with Filament Health, for a whole-leaf coca extract drug candidate aimed at post-GLP-1 weight loss management.
In a 20-day mouse study on a high-fat diet, the extract prevented weight gain without reducing food intake or increasing activity.